Core Viewpoint - The announcement by the company regarding the completion of Phase III clinical trials for its high-titer human diploid rabies vaccine marks a significant advancement towards commercialization, establishing a solid foundation for future market entry [1] Group 1: Product Development and Innovation - The newly developed high-titer human diploid rabies vaccine represents a major technological upgrade in the rabies vaccine field, demonstrating significantly higher efficacy compared to existing human diploid vaccines [1][2] - The vaccine utilizes human diploid cells instead of Vero cells, providing a natural safety advantage and resulting in a product that is 3 to 5 times more expensive than traditional Vero cell vaccines, thus offering higher added value [1][2] Group 2: Market Potential and Demand - China is projected to become the largest rabies vaccine market globally, with an estimated market value of 14.8 billion yuan by 2030, driven by product updates and increased vaccination rates [2] - The new vaccine offers flexible administration methods, including the "five-dose method," "simple four-dose method," and "2-1-1 four-dose method," making it more convenient for healthcare providers [2] Group 3: Competitive Position and Future Outlook - The company is the second-largest supplier of rabies vaccines globally and aims to lead in technological upgrades within the rabies vaccine sector, enhancing product quality and safety [3] - The approval of this new product is expected to enrich the company's product portfolio, strengthen its core competitiveness, and contribute additional revenue, thereby supporting sustainable growth [3]

Core Viewpoint - The announcement by Ai Mei Vaccine (06660.HK) indicates the successful completion of Phase III clinical trials for its high-efficacy human diploid rabies vaccine, marking a significant step towards commercialization [1] Group 1: Product Development - The new human diploid rabies vaccine features a significantly higher efficacy compared to existing products on the market, representing a major technological upgrade in the rabies vaccine field [1] - Animal trials have shown that the vaccine generates a high level of protective antibodies, outperforming currently available human diploid rabies vaccines under the same dosage conditions [1] Group 2: Market Position and Strategy - The World Health Organization (WHO) recommends human diploid rabies vaccines as the gold standard, and the company is positioned as the second-largest supplier of rabies vaccines globally [1] - The company aims to lead the technological upgrade in the rabies vaccine market, providing higher quality and safer vaccine products, thereby reinforcing its leading position and promoting sustainable development [1] Group 3: Future Prospects - The approval of this new product is expected to enhance the company's product portfolio, creating synergies with existing rabies vaccine series and strengthening its core competitiveness [1] - As part of its global strategy, the new vaccine is anticipated to contribute additional revenue and solidify the company's market position, providing new momentum for sustained and stable growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 本 公 告 由 艾 美 疫 苗 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 本 集 團 的 最 新 業 務 發 展。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：06660） 自願性公告 本 集 團 研 發 的 迭 代 工 藝 高 效 價 人 二 倍 體 狂 犬 疫 苗，目 前III期臨床現場工 作 已 順 利 完 成。這 標 誌 著 該 疫 苗 正 式 進 入 新 的 階 段，為 未 來 商 業 化 上 市 奠 定 堅 實 的 基 礎。 該 產 品 是 一 款 迭 代 升 級 的 人 二 倍 體 狂 犬 ...

Core Viewpoint - Exegenesis Bio Inc. has submitted its listing application to the Hong Kong Stock Exchange, with CCB International acting as the sole sponsor, highlighting its innovative AAVarta and SODA technology platforms for developing a diverse and scalable product pipeline [1]. Group 1: Company Overview - Exegenesis Bio Inc. is registered in the Cayman Islands and is focused on biotechnology [2]. - The company is developing core candidate products, including EXG001-307 for SMA type 1, along with two key candidates, EXG102-031 and EXG202 [1]. Group 2: Financial Details - The company has set a nominal value of $0.00001 per share for its stock [2]. - Additional costs associated with the share issuance include a 1.0% brokerage commission, transaction fees from the Securities and Futures Commission, and other exchange-related fees [2].

智通财经APP获悉，据港交所1月14日披露，Immvira Bioscience Inc.(简称：亦诺微医药)向港交所主板递交上市申请，花旗、中金公司为其联席保 荐人。据悉，亦诺微医药曾于2025年6月25日向港交所主板提交上市申请。招股书故露，亦诺微医药是一家专注于临床需求导向的生物科技公 司，致力于发现、开发、生产及商业化新型溶瘤免疫疗法和工程化外泌体疗法。公司已建立一条产品管线，包括：(i)两款针对实体瘤的溶瘤免疫 疗法产品，及 (ii)五款具临床应用前景或可直接商业化的工程化外泌体产品。公司自主研发的核心产品MVR-T3011是一款II期阶段的单纯庖疹病毒 1型(HSV-1)新型溶瘤免疫疗法产品，结合强效肿瘤溶解作用与抗PD-1抗体及IL-12的表达。 citi 花旗 CICC中金公司 (於開曼群島註冊成立的有限公司) [編纂] 每股[編纂][編纂]港元,另加1.0%經紀佣金、 最高[编纂] : 0.0027%證監會交易徵費、0.00015%會財局交 易 徵 費 及 0.00565 % 聯 交 所 交 易 費 ( 編 纂 ] 時 須 以港元全額繳付,多繳股款可予退還) 聯席保薦人、[編纂] ImmVi ...

Group 1 - The company achieved a significant milestone by commercializing its CAR-T therapy, Zevokiorunsai (CT053), for the treatment of relapsed/refractory multiple myeloma (R/R MM), marking a successful transition from research to commercialization [1] - Zevokiorunsai received NMPA approval in February 2024, becoming one of the first BCMA-targeted CAR-T drugs approved in China, with a 71.6% sCR/CR rate among R/R MM patients [1] - The company has established a deep collaboration with East China Pharmaceutical, which has formed a dedicated commercialization team to promote Zevokiorunsai, with over 111 valid orders received [1] Group 2 - The company is advancing its pipeline in solid tumors with its core product, Shurujikiorunsai (CT041), targeting CLDN18.2 for gastric and gastroesophageal junction adenocarcinomas, which has entered the NDA stage [2] - CT041 demonstrated significant improvements in progression-free survival (mPFS) and overall survival (mOS) in clinical trials, particularly in patients with CLDN18.2 positive G/GEJC [3] Group 3 - The company is developing a universal CAR-T platform, THANK-u Plus, aimed at standardizing and scaling cell therapy production, with promising results in overcoming immune rejection issues [3] - CT0596, targeting BCMA, has received IND applications for clinical trials in R/R MM and primary plasma cell leukemia (pPCL), while CT1190B is in trials for R/R B-NHL [4] Group 4 - Preliminary results for CT0596 in R/R MM show a median follow-up of 4.14 months, with 6 out of 8 evaluable patients achieving at least partial response, and no severe adverse events reported [4] - The company has a pipeline for in vivo CAR-T therapies, demonstrating significant efficacy in mouse models for targeting CD19/CD20 [4] Group 5 - Revenue projections for the company are estimated at 118 million, 310 million, and 714 million yuan for 2025, 2026, and 2027 respectively, with net losses expected to decrease over the same period [4]

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. announced a share reduction plan involving some directors and senior management due to personal financial needs related to tax obligations from the stock option incentive plan [3][10]. Summary by Sections Shareholding Information - As of the announcement date, key personnel hold the following shares: - Ms. Zhuang Zhihua: 208,930 shares (0.1857% of total shares), with 121,098 shares held indirectly through an employee stock ownership platform [2]. - Mr. Qi Yubai: 163,872 shares (0.1457% of total shares), with 118,625 shares held indirectly [2]. - Mr. Yin Jianfeng: 116,818 shares (0.1038% of total shares), with 76,894 shares held indirectly [2]. Reduction Plan Details - The reduction plan includes: - Ms. Zhuang Zhihua: up to 21,958 shares (0.0195% of total shares) - Mr. Qi Yubai: up to 11,311 shares (0.0101% of total shares) - Mr. Yin Jianfeng: up to 9,981 shares (0.0089% of total shares) - The reduction period is set for three months starting 15 trading days after the announcement [3][6]. Background on Shareholding - The mentioned directors and senior management have not reduced their holdings since the company went public on October 25, 2022 [5]. Compliance and Commitments - The reduction plan aligns with previous commitments made under the 2021 stock option incentive plan, which restricts the transfer of shares for 36 months post-exercise [8][9]. - The company confirms that the reduction does not violate any regulations regarding shareholding reductions [11].

Core Insights - The PD-(L)1 inhibitor industry is at a pivotal development point, with Hansai Aitai (3378.HK) breaking through traditional frameworks through innovative mechanisms, particularly with its two key pipelines, HX009 and HX044, marking a new chapter in tumor immunotherapy [1] Group 1: Product Innovations - HX009 is a bispecific antibody fusion protein targeting both CD47 and PD-1, achieving historic breakthroughs by reactivating exhausted T cells and demonstrating superior anti-tumor activity compared to traditional therapies [2] - HX009 has shown excellent safety at a dosage of 10 mg/kg, with no severe hematologic toxicity, and has demonstrated clear clinical activity in refractory patients previously treated with PD-1 [2] - HX044, the world's first CTLA-4/CD47 bispecific antibody, utilizes a unique design to optimize dual-target affinity, effectively targeting Treg cells within tumors while preserving peripheral normal Treg and red blood cells [2] Group 2: Clinical Development - HX009 has successfully completed Phase I clinical trials and is advancing rapidly into Phase II studies for multiple cancers, including advanced melanoma and EBV-positive non-Hodgkin lymphoma, and has been approved for combination therapy with Enhertu for advanced triple-negative breast cancer [2] - HX044 has initiated clinical trials in Australia and China and has been approved for use in combination with PD-1 for treating advanced solid tumors, potentially reshaping the competitive landscape of solid tumor immunotherapy [2][3] Group 3: Competitive Advantage - Hansai Aitai has established an unreplicable core competitive advantage through forward-looking mechanism exploration, disruptive molecular design, and solid clinical data, effectively addressing the toxicity issues of traditional CD47 therapies [3] - The company aims to continue deepening its exploration of the new CD47 mechanism and accelerate the clinical translation of more innovative drugs, leveraging its strong pipeline value to empower industry development [3]

Summary of Compass Therapeutics FY Conference Call Company Overview - **Company**: Compass Therapeutics (NasdaqCM:CMPX) - **Industry**: Oncology, specifically monoclonal antibody discovery and development - **Location**: Boston, Massachusetts - **Pipeline**: Four drugs in clinical development, with Tevesemig being the most advanced Key Points on Tevesemig - **Drug Description**: Tevesemig is a DLL4 VEGF A bispecific antibody, functioning as a next-generation angiogenesis inhibitor [1] - **Clinical Trials**: - Achieved primary endpoint in a randomized study for advanced biliary tract cancer [2] - Presented phase II data at ASCO GI showing monotherapy efficacy in advanced colorectal cancer [2] - Ongoing study COMPANION-002 comparing Tevesemig plus paclitaxel to paclitaxel alone in second-line treatment for advanced biliary tract cancer [6] - **Efficacy Data**: - Tevesemig tripled the overall response rate compared to control, with a complete response noted [7] - Significant difference in progression-free survival (PFS) observed, with 42.1% progression in control vs. 16.2% in combination arm at week eight [9] - More than 20% of patients alive at 18 months, compared to less than 10% in FOLFOX regimen [10] - **Market Opportunity**: - Estimated 25,000 new patients annually in the U.S. with biliary tract cancer, with a treatable population of approximately 15,000 [11] - Potential for over $1 billion annual market in second-line biliary tract cancer [11] - **Future Plans**: - Plans to expand indications post-approval, targeting other cancers like colorectal and gastric [12] - Potential to replace Avastin in various indications [13] Other Drug Developments - **CTX471**: - A CD137 agonist antibody showing nearly 30% response rate in post-PD1 melanoma patients [15] - Notable case of a patient with metastatic small cell lung cancer achieving a complete response after multiple therapies [16] - Planning an NCAM-positive basket study to explore efficacy further [17] - **CTX8371**: - A PD1/PDL1 bispecific antibody demonstrating unique T cell engagement and potential to convert PD1-positive T cells to PD1-negative [19] - Responses observed in patients with triple-negative breast cancer and Hodgkin's lymphoma [21] - Ongoing cohort expansions for further evaluation [21] - **CTX10726**: - A novel PD1/VEGF-A bispecific antibody entering clinical trials, showing superior preclinical efficacy compared to leading competitors [22][38] - Expected to initiate phase 1 study this quarter, with clinical data anticipated in the second half of the year [40] Commercialization Strategy - **Tevesemig**: - Plans to commercialize independently in the U.S. due to the specialized nature of the patient population [31] - Open to strategic partnerships for international markets [32] - **Infrastructure Development**: - Building commercial infrastructure over the next 12-18 months in preparation for drug launch [36] Conclusion - Compass Therapeutics is positioned for significant growth with its innovative pipeline, particularly Tevesemig, which has the potential to transform treatment for advanced biliary tract cancer and other malignancies. The company is actively preparing for commercialization and exploring further clinical opportunities across its drug portfolio.

Core Viewpoint - The company Valiant Biopharma-B (09887) has received Fast Track designation from the FDA for its PD-L1/4-1BB bispecific antibody, Valiant (Opatasumab, LBL-024), aimed at treating pulmonary neuroendocrine carcinoma, which accelerates the drug development process for serious conditions [1][2]. Group 1: Drug Development and Regulatory Milestones - Valiant is the first bispecific antibody targeting both PD-L1 and 4-1BB to reach the registration clinical stage for pulmonary neuroendocrine carcinoma [2]. - The Fast Track designation allows for more frequent regulatory interactions and the ability to submit a rolling New Drug Application (NDA) [1]. - The company has received Breakthrough Therapy Designation (BTD) from the NMPA for Valiant in treating advanced pulmonary neuroendocrine carcinoma, and Orphan Drug Designation (ODD) from the FDA for neuroendocrine carcinoma [2]. Group 2: Clinical Efficacy and Safety - In clinical trials in China, Valiant has shown promising efficacy signals and good safety profiles as both a monotherapy and in combination with chemotherapy for advanced pulmonary neuroendocrine carcinoma [2]. - The drug exhibits strong clinical activity potential in multiple indications, including non-small cell lung cancer, small cell lung cancer, and pulmonary neuroendocrine carcinoma [2]. - Valiant's design aims to overcome PD-1/L1 immune suppression and enhance T cell activation, indicating a broader cancer treatment potential compared to PD-1/L1 inhibitors [2]. Group 3: Broader Implications and Future Potential - 4-1BB as an agonist can reactivate exhausted T cells, making it suitable for treating "cold tumors" resistant to PD-1/PD-L1 therapies [3]. - Valiant has shown encouraging clinical signals in various cancers with unmet medical needs, including small cell lung cancer, cholangiocarcinoma, ovarian cancer, and triple-negative breast cancer [3]. - The drug is positioned to become a promising anti-tumor agent across a wide range of indications [3].